Clinical Report: Sleep Apnea’s Overlooked Role in Pregnancy
Overview
Pregnant patients with obstructive sleep apnea (OSA) face significantly higher risks of preeclampsia and other adverse outcomes. This narrative review highlights the need for improved recognition and management of OSA in pregnancy to mitigate maternal and fetal risks.
Background
Obstructive sleep apnea is a common condition that can lead to serious complications, particularly during pregnancy. The physiological changes associated with pregnancy often mask the symptoms of OSA, resulting in underdiagnosis. Recognizing and addressing OSA is crucial for improving maternal and fetal health outcomes.
Data Highlights
Pregnant patients with OSA have 2- to 3-fold higher odds of preeclampsia and are more likely to require intensive care. Treatment with positive airway pressure has shown potential benefits, though adherence varies.
Key Findings
OSA in pregnancy is linked to higher odds of preeclampsia, gestational hypertension, and gestational diabetes.
Fetal outcomes include increased risks of preterm birth and neonatal respiratory complications.
Common screening tools for OSA have modest sensitivity and specificity in pregnant populations.
Polysomnography remains the gold standard for diagnosing OSA, while home sleep testing is feasible for high-risk patients.
Continuous positive airway pressure therapy may improve some cardiometabolic and hypertensive outcomes in pregnant patients.
Clinical Implications
Healthcare providers should be vigilant in screening for OSA in pregnant patients, especially those with risk factors such as obesity and chronic hypertension. Early diagnosis and management can significantly improve maternal and fetal health outcomes.
Conclusion
Recognizing and treating obstructive sleep apnea in pregnancy is essential to prevent serious complications and improve overall health outcomes for mothers and their infants.
A four-factor staging system stratified response rates from 90.9% to 37.5% in a retrospective cohort study, although the model showed only moderate discrimination (C statistic, 0.68) and requires external validation
A retrospective cohort study of more than 520,000 hospitalized patients found no clinically meaningful improvement in deterioration or mortality with early treatment targeting community-acquired pneumonia.